Reviewer's report


**Title:** Establishment of Hewga-clear cell sarcoma, a new clear cell sarcoma cell line, and investigation of the antitumor effects of pazopanib on Hewga-CCS: an in vitro and in vivo study

**Version:** 1  
**Date:** 30 April 2014

**Reviewer:** shashwat sharad

**Reviewer's report:**

The manuscript is well written and authors did the outstanding work. The study is well designed. Data, Discussions and conclusions are good.

The Minor suggestions are

**Minor Essential Revisions**

**Title:**
The author should consider to revised the title for better readability

**Abstract**

1. First paragraph Background section - explain EWS
2. Third paragraph Result section - explain HMB-45
3. It is not clear why the authors want to develop this cell line, when other cell lines are available.

**Background**

1. First paragraph explain - M-MITF, S-100 and HMB45.
2. First paragraph - Please provide the reference for approximately "50% patients develop nodal metastases"
3. First paragraph - Please rephrase the sentence "CCS is molecularly defined resulting in the EWSR1-ATF1 (EWS-ATF1) fusion oncoprotein [12,13]."
4. Paragraph 2 - It is not clear why this Hewga-CCS cell line is is developed when other cell lines are available to study CCS. Authors should also tried to explore the the effect of Pazopaib in other available cell lines.

**Methods**

1. Chromosomal analysis - Please explain the method in detail.
2. Cell proliferation assay - Please provide the passage number of the Hewga -CCS cells used

**Results**

Characterization of the Hewga cell line - It is not clear why 20% FBS is used for
spheriod formation.

Level of interest: An article of outstanding merit and interest in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.